O rthopaedic implant-associated infections (OIAIs) are serious complications in orthopaedic surgery [1] [2] [3] . Periprosthetic joint infections (PJIs) occur in 1% to 2% of primary and 3% to 6% of revision arthroplasties [4] [5] [6] , and infection in open fractures treated with intramedullary nailing occurs in up to 30% of cases 7, 8 . These percentages correspond to ;25,000 PJIs and ;100,000 fracture-fixation device-related infections in the U.S. annually 9, 10 , which are increasing with clinical demand 11 . In vivo bioluminescence imaging (BLI) provides the opportunity of noninvasive monitoring of the bacterial burden in animal models of OIAI to study pathogenesis [12] [13] [14] [15] [16] [17] [18] [19] [20] emission from live and actively metabolizing bacteria that can be measured by an in vivo imaging system (IVIS) 34 . However, insufficient bacterial light production, poor light penetration through deep tissues, and IVIS machines that are configured for rodents have limited in vivo BLI to mouse and rat models of OIAI 34 . Highlighting this limitation, BLI could only be performed post mortem in a rabbit knee-joint OIAI model after removal of overlying musculoskeletal tissues and opening of the joint capsule 35 . If in vivo BLI could be expanded to larger-animal models of OIAI in which complex orthopaedic surgical procedures and implants can be used, clinical relevance may be greatly improved 36, 37 . This prompted us to develop a rabbit model of OIAI in which in vivo BLI was used to assess the preclinical efficacy of an antibiotic-releasing implant coating that was previously demonstrated to be effective in a mouse model of OIAI 23 .
Materials and Methods

Antibiotic-Loaded Implant Coating
T o generate a poly(D,L-lactic-co-glycolic acid) (PLGA) and poly(e-caprolactone) (PCL) nanofiber coating loaded without (designated "2/2") or with (linezolid [Lin] in PLGA and PCL and rifampin [Rif] in PCL, designated "Lin/Lin 1 Rif ") antibiotics, previous methods were modified 23 . Rifampin was used in combination with linezolid to prevent the development of rifampin-resistant bacteria if rifampin were to be used alone. First, orthopaedic-grade titanium locking pegs (2 · 24 mm; Zimmer Biomet) were etched by incubating in 5 M NaOH solution at 37°C for 8 hours (Fig. 1 ). After rinsing with deionized water and drying in a lyophilizer for 24 hours, implants were dipped (insertion/removal speed of 0.25 cm/sec) in a solution of poly(L-lactic acid) (PLA polymer 6201D; NatureWorks) dissolved in dichloromethane (10.0 w/w%). PLGA (75:25, molecular weight [MW] 66,000 to 107,000) was dissolved in hexafluoro-2-propanol (10.0 w/w%) ± linezolid (1.0 w/w%) (all Sigma-Aldrich). PCL (MW 200,000; PolySciTech) was dissolved in dichloromethane and isopropanol (75:25, 5.0 w/w%; Sigma-Aldrich) ± linezolid (0.1 w/w%; Santa Cruz Biotechnology), rifampin (0.5 w/w%; Sigma-Aldrich), and NaCl (0.1 w/w%). For co-electrospinning, solutions of PLGA and PCL were loaded into separate 1-mL syringes fitted with blunt-end 27-gauge needles. High-power voltage sources were connected via alligator clips to each needle tip and supplied with 6 to 7-kV voltage between the needles and the implant. Two syringe pumps were used to feed the PLGA (25 mL/hr) and PCL (1.5 mL/hr) polymer solutions. PLGA and PCL nanofibers were collected simultaneously and directly onto the grounded etched/PLA-coated implants at a distance of 10 cm with the implants held by a rotary tool grip at each distal end for 8 and 7 minutes, respectively. Co-electrospinning was performed to coat the implants with PLGA and PCL nanofibers loaded with or without antibiotics. The coated implants were annealed for 15 minutes at 70°C to generate a conformal PCL and PLGA fiber coating; residual solvent was removed by overnight lyophilization.
Scanning Electron Microscopy
The implants were sputter-coated with gold-palladium alloy and imaged with a field-emission scanning electron microscope (JSM-6700F field-emission scanning electron microscope [FE-SEM]; JEOL) ( Fig. 1) , as previously described 23 .
In Vitro Antibiotic Release Implants with the antibiotic-loaded coatings were submerged in 1 mL of phosphate-buffered saline (PBS) solution (pH 7.4) at 37°C, and the drug-release medium was changed daily for 18 days and stored at 220°C. Antibiotic concentrations in the drug-release media were quantified by high-performance liquid chromatography (HPLC) using wavelengths for linezolid (254 nm) and rifampin (263 mm), as previously described 23 .
Bacteria
The bioluminescent Staphylococcus aureus strain SAP231 (provided by Roger Plaut, U.S. Food and Drug Administration [FDA]) possesses a stably integrated lux construct in the bacterial chromosome previously generated from the NRS384 methicillin-resistant S. aureus (MRSA) strain 38 . SAP231 was streaked onto tryptic soy agar (TSA) plates and incubated overnight at 37°C. Individual colonies were cultured in tryptic soy broth (TSB) overnight at 37°C with shaking (240 rpm). A 1: 50 dilution of the overnight culture was subcultured for 2 hours at 37°C with shaking, and bacteria were washed in PBS solution and reconstituted to an inoculum of 1 · 10 4 CFUs (colonyforming units) in 10 mL of PBS solution as determined by absorbance at 600 nm (A 600 ) and confirmed by overnight culture on plates.
In Vitro Antimicrobial Assay Mid-logarithmic-phase SAP231 was prepared as above and diluted to 1 · 10 3 CFU/mL in Cation-Adjusted Mueller Hinton II Broth (Becton Dickinson), pH 7.3. Bacteria were cultured 1: 1, with drug-release media collected daily (see above) for 18 days at 37°C, and CFUs were enumerated by absorbance (A 600 ) and a CFU standard curve.
Rabbit Model of OIAI All procedures were approved by the Johns Hopkins Animal Care and Use Committee. A sample size of 6 rabbits per group was chosen for this proof-of-concept study. Ten to 16-week-old male Dutch Belted rabbits (Robinson Services) (;2 kg body weight) were anesthetized via intramuscular injection of a mixture of ketamine (25 mg/kg) and xylazine (1.5 mg/kg) (ZooPharm), and maintained with isoflurane (1.5%). Sterile ophthalmic ointment (Rugby) was applied to the eyes.
For each rabbit, sustained-release buprenorphine (ZooPharm) (0.2 mg/kg) and sustained-release meloxicam (Norbrook Laboratories) (0.6 mg/dose) were injected subcutaneously for analgesia. Metoclopramide (Teva) (0.3 mg/kg) was injected subcutaneously as a gastrointestinal promotility agent. The distal anterior region of the right thigh through the proximal aspect of the leg was shaved and prepared with isopropyl alcohol (70%) followed by povidone-iodine (10%), each e12(2) 20, 2019 applied 3 times ( Fig. 2-A) . In slight knee flexion, a midline incision and a medial parapatellar arthrotomy were performed ( Fig. 2-B) , and the patella was dislocated laterally to expose the trochlea and intercondylar notch ( Fig. 2-C) . In maximal knee flexion, a 2-mm drill-bit was used to access the femoral canal just anterior to the Blumensaat line ( Fig. 2-D) , and a 2.2-mm Figs. 1-A through 1-D Antibiotic-loaded implant coating. Fig. 1 -A The nanofiber antibiotic-releasing coating was prepared using base-etched orthopaedic-grade titanium peg implants, which were then dip-coated in PLA dissolved in dichloromethane (PLA/DCM) solution. Co-electrospinning was performed to coat the implants with PLGA and PCL nanofibers loaded with or without antibiotics followed by heat treatment (annealing) to generate a conformal PCL and PLGA fiber coating. Fig. 1 -B Representative scanning electron microscopy images of the implant and nanofiber coating surfaces after each step in the coating process. 20, 2019 drill-bit was used to countersink the implant. SAP231 (1 · 10 4 CFUs in 10 mL PBS solution) was pipetted into the canal ( Figs. 2-A through 2-I Rabbit surgical procedures. Fig. 2 -A The distal anterior region of the right thigh through the proximal aspect of the leg was shaved and prepared. Fig. 2 -B After a midline incision was made over the patella, a medial parapatellar arthrotomy was performed. 20, 2019 Vicryl sutures (Ethicon) (Fig. 2-H ). An anteroposterior radiograph (1 per rabbit) confirmed implant placement (Faxitron MX-20; Faxitron Bioptics) ( Fig. 2-I ).
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In Vivo BLI Each rabbit was anesthetized via intramuscular injection of ketamine (25 mg/kg) and xylazine (1.5 mg/kg) (ZooPharm) and muscle/tendon tissue, bone, and implant specimens harvested and processed on day 7 to determine ex vivo CFUs. Fig. 3 -B Representative images of the tissue processing, with the empty blender cartridge (left panel), placement of a muscle/tendon specimen in the blender (middle panel), and the appearance of liquid homogenates after blending (right panel). Similar procedures were used for homogenizing the bone specimens. 20, 2019 and positioned semi-upright in the IVIS Lumina III chamber (PerkinElmer), with the postoperative right knee almost maximally flexed and positioned underneath the CCD (charge-coupled device) camera. In vivo BLI signals were acquired (5-minute exposure and medium binning), overlaid onto a grayscale photograph, and quantified as total flux (photons/sec) within e12 (6) T 20, 2019 an oval region of interest (3 · 4 cm) using Living Image software (PerkinElmer).
Knee-Width Measurement
The postoperative knee was maximally flexed and the maximal medial-lateral width of the knee joint was measured manually with a Pittsburgh digital caliper (Harbor Freight Tools) by an investigator who was not blinded to the treatment group.
Ex Vivo CFU On day 7, rabbits were killed and each muscle/tendon (i.e., muscle and tendon) tissue specimen was placed in a blender or with (Lin/Lin 1 Rif) antibiotics (n = 6 rabbits per experimental group). *P < 0.05, yp < 0.01, and zp < 0.001, 2/2 versus Lin/Lin 1 Rif, as calculated by 2-way ANOVA ( Fig. 5-B) , 2-tailed Student t test (Fig. 5-C) , or 2-tailed Fisher exact test (Fig. 5-D) . n.d.= none detected. 
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T 20, 2019 container with 200 mL of PBS solution, each femur was manually crushed and placed in a blender container with 50 mL of PBS solution, and each implant was placed in a conical tube with 2 mL of TSB with 0.3% TWEEN 20 (Sigma-Aldrich). Each tissue and bone specimen was separately homogenized at 20,000 rpm for 30 to 120 seconds in a commercial blender (7011HS; Waring). To isolate bacteria adherent to the implants, each implant was vortexed for 2 minutes (10,000 rpm), sonicated for 10 minutes, and vortexed again for 2 minutes. Serial dilutions of each tissue homogenate or sonicate solution were plated and CFUs counted after overnight culture at 37°C. To detect S. aureus persisters and small-colony variants, each sonicate solution was incubated at 37°C with shaking (240 rpm) for an additional 48 hours, followed by another 48-hour culture on plates 39 .
Statistical Analysis
Data were analyzed using Prism software (GraphPad) and are presented as the mean and standard error of the mean (SEM). Data were compared by a 2-tailed Student t test, 2-way analysis of variance (ANOVA), or 2-tailed Fisher exact test (see figure  legends) . P values of <0.05 were considered significant.
Results
Generation of an Antibiotic-Loaded Implant Coating
T o generate an implant coating that releases antibiotics for at least 7 days, previous techniques were modified, as described above 23 . The implants were base-etched and dipped in PLA, co-electrospun with PLGA and PCL loaded with (Lin/ Lin 1 Rif) or without (2/2) antibiotics, and annealed. In vitro analysis indicated that linezolid and rifampin were released above the minimum inhibitory concentration (MIC) for 8 to 10 days, and in vitro S. aureus growth was not observed until day 10 ( Fig. 1) .
Rabbit Model of OIAI
The rabbit model of OIAI was utilized whereby the right femoral canal was reamed followed by MRSA inoculation and placement of Lin/Lin 1 Rif or 2/2 coated implants (Fig. 2) .
Timeline for BLI and CFU Enumeration
In vivo BLI was performed on anesthetized rabbits on days 0, 4, and 7. Rabbits were killed on day 7, and tissue and bone specimens were separately homogenized and implants were sonicated to assess ex vivo CFUs (Fig. 3) .
Efficacy of the Antibiotic-Releasing Coating
To assess infection-induced inflammation, knee width was measured on days 0, 4, and 7 ( Fig. 4-A) . The 2/2 group demonstrated a 36% increase in knee width; this was significantly greater than that in the Lin/Lin 1 Rif group, which maintained the same knee width as that seen at baseline (p < 0.001) (Fig. 4-B and Table I ). For assessment of the joint tissue, rabbits were killed on day 7 and the overlying skin was removed. The knee-joint tissue was purulent and friable in the 2/2 group, whereas it appeared normal in the Lin/ Lin 1 Rif group (Fig. 4-C) .
In vivo BLI revealed high bacterial bioluminescent signals with the 2/2 coating on days 4 and 7 (peaking on day 4), with total flux values significantly greater than those of the Lin/ Lin 1 Rif coating (p < 0.05), which remained below the limit of detection on all postoperative days (Figs. 5-A and 5-B and Table  I ). To confirm in vivo BLI data, rabbits were killed on day 7 and ex vivo CFUs enumerated. The rabbits with the 2/2 coating had increased CFUs isolated from the tissue (p < 0.001), bone (p < 0.05), and implant (p < 0.05) specimens compared with those with the Lin/Lin 1 Rif coating, which had undetectable CFUs from all sources (Fig. 5-C and Table II) . Finally, sonicates from the implants were cultured for an additional 48 hours in broth followed by another 48 hours on plates to evaluate for any remaining S. aureus bacteria. All of the 2/2 coating sonicates had bacterial growth, whereas no bacterial growth was detected from Lin/Lin 1 Rif coating sonicates (Fig. 5-D) .
Discussion
O IAI complications result in increased morbidity, mortality, and health-care costs and worse clinical outcomes [1] [2] [3] . Efforts to elucidate pathogenesis and enhance diagnosis and treatment have used preclinical models of OIAI, but current small-animal models lack complex procedures and surgicalgrade implants, and in vivo BLI for monitoring infection has not been feasible in larger animals 36, 37 . Herein, we described the development of a rabbit model of OIAI using in vivo BLI and demonstrated the efficacy of an antibiotic-releasing implant coating to prevent an MRSA OIAI.
To the best of our knowledge, this is the first largeranimal model of OIAI to incorporate in vivo BLI to noninvasively and longitudinally monitor the bacterial burden. This was accomplished by using a bright bioluminescent MRSA strain (SAP231) in which the lux operon was inserted into a e12 (8) pseudogene under the control of a strong constitutively active promoter 38 . In mouse models of OIAI, the SAP231 strain produced in vivo BLI signals that were a log unit higher 31, 33 than multiple other bioluminescent S. aureus strains 20 . In addition, for the rabbit OIAI model, we used Dutch Belted rabbits because the adults are small enough to fit within the standard chambers of existing IVIS machines.
This new capability is advantageous for the preclinical investigation of OIAI. First, this rabbit model of OIAI used a clinically applied orthopaedic implant, and the involvement of distinct tissue layers during the surgical approach and closure replicated a medial parapatellar arthrotomy in humans. Second, we chose an orthopaedic implant that was threaded within the intercondylar bone to reproduce the initially stable implants in clinical OIAI 40 , which is an improvement over smooth Kirschner-wire implants commonly used in mouse models of OIAI 37 . Third, the use of in vivo BLI substantially reduces animal numbers because euthanasia at multiple time points is not required to obtain CFU data; minimizes pain and distress because invasive sampling techniques are not required to obtain tissue or joint fluid; and can be used to determine relevant time points for additional investigation. Fourth, S. aureus virulence factors such as Panton-Valentine leukocidin (PVL) are active in rabbits (and humans) but not in mice, suggesting that rabbits represent a more clinically relevant animal model for studying S. aureus infections 41 . Collectively, this rabbit OIAI model using in vivo BLI will permit preclinical evaluation of local and systemic antibiotics, biomaterials, and diagnostics in a larger animal model of OIAI, while reducing animal numbers and experimental costs for larger-animal studies.
We previously reported that a PLGA and PCL coelectrospun coating loaded with antibiotics (vancomycin, daptomycin, or linezolid combined with rifampin) prevented infection in a mouse model of OIAI 23 . PLGA and PCL are biocompatible, bioresorbable, and clinically used materials in sutures and drug-delivery devices 42, 43 . We found that PLGA releases drugs more slowly than PCL, and various configurations of 1 or 2 (or multiple) antibiotics loaded onto each or both types of nanofibers can lead to different drug-elution concentrations and durations of release for optimal efficacy. Thus, the coating is highly versatile, and the polymers or drug concentrations could be modified for more rapid or longer release if desired 23 . Theoretically, any antibiotic that is heat-stable up to 65°to 70°C could be incorporated into this nanofiber coating, so it could provide coverage against monomicrobial and polymicrobial infections. The co-electrospinning coating technique is rapid and simple, requiring only a voltage source connected to the coating solutions to deliver them to a rotating implant, and can be applied to any metallic orthopaedic implant during the manufacturing process. An advance was made in which base-etching and adding a PLA primer prior to the co-electrospun PLGA and PCL coating were performed to enhance the coating durability to withstand the surgical procedures in the rabbit model.
There were limitations to our study. First, investigations involving rabbits might not fully translate to human OIAI. However, we used orthopaedic-grade implants, clinically relevant antibiotics, and PLGA and PCL polymers that are currently in clinical use 42, 43 . Second, while the rabbit group size was small (n = 6 per group), it was sufficient to determine significance for all end points. Third, the in vivo BLI signals in the rabbit OIAI model likely corresponded to soft-tissue infection, as there were >10-fold and >100-fold greater ex vivo CFUs isolated from the tissue than from the bone and implant specimens, respectively. Furthermore, in vivo BLI signals are also affected by bacterial metabolic activity and growth that is higher when bacteria are in the tissue, as previously described for a mouse model of OIAI in which in vivo BLI signals peaked on postoperative days 2 to 4 during transition from planktonic to biofilm growth 17 . Finally, prolonging the study beyond 7 days could provide the opportunity to acquire insights into osteolysis or implant migration as seen in more chronic infections. However, rabbits are sensitive to anesthesia and thus cannot undergo imaging more than every 3 days. In a pilot experiment, rabbits with implants lacking the antibiotic coating were followed for 14 days, but this resulted in a more severe local OIAI causing unnecessary animal suffering (the rabbits no longer would use or bear weight on the infected leg) and all subsequent experiments were thus ended at 7 days. Our future work using this rabbit model of OIAI will address whether bacterial invasion and colonization of the osteocytic-canalicular network occurs as previously described [44] [45] [46] and will evaluate other antibiotic-release strategies for different infections, such as those involving indolent and gram-negative bacteria, as well as more chronic infections.
In conclusion, our findings provide proof of concept for combining a larger-animal model of OIAI with noninvasive in vivo BLI technology to potentially translate findings from preclinical animal models of OIAI to humans. n 
